Chronic Lymphocytic Leukemia Specialty Channel

Chronic Lymphocytic Leukemia

Specialty Channel

Conference Coverage

Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL

06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...

At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...

At the 65th ASH Annual Meeting,...

06/26/2024

Oncology

News

Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL

04/18/2024

Amber Denham

According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.

According to phase 3b results...

04/18/2024

Oncology

FDA Approval

FDA Approves Lisocabtagene Maraleucel for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

03/25/2024

Amber Denham

The FDA granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least 2 prior lines of therapy, including a BTK...

The FDA granted accelerated...

03/25/2024

Oncology

News

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab Followed by Ibrutinib Maintenance Continues to Demonstrate Deep, Durable Responses for Patients With Previously Untreated CLL

03/15/2024

Amber Denham

According to 5-year follow-up data, ibrutinib plus fludarabine, cyclophosphamide, and rituximab followed by 2 years of ibrutinib maintenance led to durably deep responses in patients with previously untreated chronic lymphocytic leukemia with...

According to 5-year follow-up...

03/15/2024

Oncology

News

Venetoclax-Obinutuzumab Demonstrates Durable, Safe Responses for Patients With R/R CLL/SLL

02/05/2024

Amber Denham

Venetoclax-obinutuzumab achieved frequent, durable, and safe responses among patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, according to a retrospective, real-world study.

Venetoclax-obinutuzumab achieved...

02/05/2024

Oncology

News

MRD-Directed Ibrutinib Venetoclax Therapy Improved Survival for Patients With Untreated CLL Compared With Fludarabine-Cyclophosphamide-Rituximab Therapy

02/05/2024

Amber Denham

Measurable residual disease-directed ibrutinib–venetoclax treatment improved progression-free survival compared with fludarabine–cyclophosphamide–rituximab treatment for patients with untreated chronic lymphocytic leukemia, according to a...

Measurable residual...

02/05/2024

Oncology

News

CD19 CAR T-Cell Therapy Achieved Durable Responses Among Specific Subset of Patients With R/R CLL

01/24/2024

Amber Denham

CD19 CAR T-cell therapy achieved durable responses among a subset of patients with high-risk, R/R chronic lymphocytic leukemia, according to a phase 1/2 study which explored factors associated with long-term outcomes.

CD19 CAR T-cell therapy achieved...

01/24/2024

Oncology

Conference Coverage

Exploring Possibilities for the Future of Chronic Lymphocytic Leukemia Treatment

01/12/2024

Featuring Adrian Wiestner, MD

At the 65th ASH Annual Meeting, Adrian Wiestner, MD, discusses exciting possibilities for the future of chronic lymphocytic leukemia treatment, including the prospect of time-limited treatment periods and T-cell-engaging bispecific antibodies.

At the 65th ASH Annual Meeting,...

01/12/2024

Oncology

News

Lisocabtagene Maraleucel Demonstrates Efficacy, Manageable Safety Among Patients With R/R CLL/SLL

11/20/2023

Amber Denham

Phase 1/2 trial results demonstrated that lisocabtagene maraleucel treatment induced complete response or remission, including with incomplete marrow recovery, among patients with R/R chronic lymphocytic leukemia or small lymphocytic lymphoma.

Phase 1/2 trial results...

11/20/2023

Oncology

Quiz

Adding Venetoclax to High-Risk Chronic Lymphocytic Leukemia Treatment

10/31/2023

The addition of venetoclax therapy among patients with high-risk chronic lymphocytic leukemia who had received at least ___ months or more of ibrutinib treatment achieved a high rate of undetectable measurable residual disease (U-MRD) in the...

The addition of venetoclax...

10/31/2023

Oncology

Quiz

Venetoclax for CLL With High-Risk Features

10/05/2023

The addition of venetoclax therapy yielded high rates of undetectable measurable residual disease (U-MRD) in the bone marrow among patients with CLL who had received ibrutinib for ≥12 months and had high-risk features, including ___.

The addition of venetoclax...

10/05/2023

Oncology

News

Conference Coverage

Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL

06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...

At the 65th ASH Annual Meeting,...

06/26/2024

Oncology

News

Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL

04/18/2024

Amber Denham

According to phase 3b results...

04/18/2024

Oncology

FDA Approval

FDA Approves Lisocabtagene Maraleucel for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

03/25/2024

Amber Denham

The FDA granted accelerated...

03/25/2024

Oncology

News

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab Followed by Ibrutinib Maintenance Continues to Demonstrate Deep, Durable Responses for Patients With Previously Untreated CLL

03/15/2024

Amber Denham

According to 5-year follow-up...

03/15/2024

Oncology

News

Venetoclax-Obinutuzumab Demonstrates Durable, Safe Responses for Patients With R/R CLL/SLL

02/05/2024

Amber Denham

Venetoclax-obinutuzumab achieved...

02/05/2024

Oncology

News

MRD-Directed Ibrutinib Venetoclax Therapy Improved Survival for Patients With Untreated CLL Compared With Fludarabine-Cyclophosphamide-Rituximab Therapy

02/05/2024

Amber Denham

Measurable residual...

02/05/2024

Oncology

News

CD19 CAR T-Cell Therapy Achieved Durable Responses Among Specific Subset of Patients With R/R CLL

01/24/2024

Amber Denham

CD19 CAR T-cell therapy achieved...

01/24/2024

Oncology

Conference Coverage

Exploring Possibilities for the Future of Chronic Lymphocytic Leukemia Treatment

01/12/2024

Featuring Adrian Wiestner, MD

At the 65th ASH Annual Meeting,...

01/12/2024

Oncology

News

Lisocabtagene Maraleucel Demonstrates Efficacy, Manageable Safety Among Patients With R/R CLL/SLL

11/20/2023

Amber Denham

Phase 1/2 trial results...

11/20/2023

Oncology

News

Ibrutinib Plus Rituximab Demonstrates Efficacy as Second-Line Treatment for Patients With CLL and R/R AIHA/PRCA

09/21/2023

Jordan Kadish

A phase 2 trial found that ibrutinib plus rituximab demonstrated efficacy among patients with CLL and steroid refractory autoimmune cytopenias such as autoimmune hemolytic anemia and pure red cell aplasia.

A phase 2 trial found that...

09/21/2023

Oncology

Interactive Features

Quiz

Adding Venetoclax to High-Risk Chronic Lymphocytic Leukemia Treatment

10/31/2023

The addition of venetoclax...

10/31/2023

Oncology

Quiz

Venetoclax for CLL With High-Risk Features

10/05/2023

The addition of venetoclax...

10/05/2023

Oncology

Quiz

Ibrutinib Plus Venetoclax Combination for Previously Untreated CLL

09/01/2023

True or False: Results of the phase 3 GLOW trial indicated that ibrutinib plus venetoclax treatment did not improve progression-free survival compared to treatment with chlorambucil and obinutuzumab among older patients with previously...

True or False: Results of the...

09/01/2023

Oncology

Quiz

FDA Approval of Zanubrutinib for CLL/SLL

05/23/2023

The FDA approved zanubrutinib for CLL or SLL based on efficacy results from the ALPINE trial, which indicated that the overall response rate among patients who received this treatment was ____.

The FDA approved zanubrutinib...

05/23/2023

Oncology

Quiz

Quiz: Overall Survival Rate of Venetoclax Plus Rituximab Treatment in Patients With Relapsed/Refractory CLL

12/01/2022

What was the overall survival rate of venetoclax plus rituximab treatment in patients with relapsed/refractory CLL at 3 years following cessation, according to a 5-year update of a phase 3 trial?

What was the overall survival...

12/01/2022

Oncology

Quiz

Quiz: Obinutuzumab in Patients With Chronic Lymphocytic Leukemia That Responded to Chemo-Immunotherapy

12/01/2022

True or false: Obinutuzumab is well-tolerated in patients with chronic lymphocytic leukemia that responded to chemo-immunotherapy, according to a phase 2/3 trial.

True or false: Obinutuzumab is...

12/01/2022

Oncology

Quiz

Quiz: Zanubrutinib as Frontline Therapy for CLL and SLL

10/12/2022

True or False: Zanubrutinib significantly improved progression-free survival vs bendamustine–rituximab as a frontline therapy for CLL and SLL.

True or False: Zanubrutinib...

10/12/2022

Oncology

Quiz

Quiz: MRD-Guided, Time-Limited Treatment With Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL

09/05/2022

True or false: MRD-guided, time-limited treatment with ibrutinib plus venetoclax may be beneficial for patients with relapsed/refractory CLL, according to a phase 2 trial.

True or false: MRD-guided,...

09/05/2022

Oncology

Quiz

Quiz: What Were the Long-term Findings From the RESONATE-2 Trial in CLL?

08/05/2022

True or false: Long-term RESONATE-2 data revealed continual benefit with first-line ibrutinib treatment for CLL, including for patients who have high-risk genomic features?

True or false: Long-term...

08/05/2022

Oncology

Test Your Knowledge

Quiz: Umbralisib Plus Ublituximab for Patients With TN, PT CLL

11/22/2021

True or false: the phase 3 UNITY-CLL study found umbralisib plus ublituximab has a tolerable safety profile and prolonged PFS compared to CIT in patients with both TN and PT CLL.

True or false: the phase 3...

11/22/2021

Oncology

Recent News

News

Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL

04/18/2024

Amber Denham

According to phase 3b results...

04/18/2024

Oncology

FDA Approval

FDA Approves Lisocabtagene Maraleucel for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

03/25/2024

Amber Denham

The FDA granted accelerated...

03/25/2024

Oncology

News

Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab Followed by Ibrutinib Maintenance Continues to Demonstrate Deep, Durable Responses for Patients With Previously Untreated CLL

03/15/2024

Amber Denham

According to 5-year follow-up...

03/15/2024

Oncology

News

Venetoclax-Obinutuzumab Demonstrates Durable, Safe Responses for Patients With R/R CLL/SLL

02/05/2024

Amber Denham

Venetoclax-obinutuzumab achieved...

02/05/2024

Oncology

News

MRD-Directed Ibrutinib Venetoclax Therapy Improved Survival for Patients With Untreated CLL Compared With Fludarabine-Cyclophosphamide-Rituximab Therapy

02/05/2024

Amber Denham

Measurable residual...

02/05/2024

Oncology

News

CD19 CAR T-Cell Therapy Achieved Durable Responses Among Specific Subset of Patients With R/R CLL

01/24/2024

Amber Denham

CD19 CAR T-cell therapy achieved...

01/24/2024

Oncology

News

Lisocabtagene Maraleucel Demonstrates Efficacy, Manageable Safety Among Patients With R/R CLL/SLL

11/20/2023

Amber Denham

Phase 1/2 trial results...

11/20/2023

Oncology

News

Ibrutinib Plus Rituximab Demonstrates Efficacy as Second-Line Treatment for Patients With CLL and R/R AIHA/PRCA

09/21/2023

Jordan Kadish

A phase 2 trial found that...

09/21/2023

Oncology

News

Venetoclax Consolidation Therapy Increased Achievement of Undetectable MRD Among Patients With High-Risk CLL

09/18/2023

Jordan Kadish

The addition of venetoclax to ibrutinib treatment among patients with high-risk chronic lymphocytic leukemia achieved a high rate of undetectable measurable residual disease in the bone marrow.

The addition of venetoclax to...

09/18/2023

Oncology

News

T-Lymphocyte Subgroups at Diagnosis Demonstrate Prognostic Value for Patients With Chronic Lymphocytic Leukemia

09/08/2023

Amber Denham

Low T-lymphocyte percentages and low T-lymphocyte/MBC ratios at diagnosis were associated with poor prognosis, progressive disease, and decreased survival among patients with previously untreated CLL, according to findings presented at the...

Low T-lymphocyte percentages and...

09/08/2023

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology